ArticleTremor and other hyperkinetic movements (New York, N.Y.)2013
An update on tardive dyskinesia: from phenomenology to treatment.
Article in Tremor and other hyperkinetic movements (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.Tremor and other hyperkinetic movements (New York, N.Y.) · 2024Pooled it
- Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway.Frontiers in neurology · 2024Pooled it
- Pooled it
- Valbenazine Sprinkle: An Alternative Formulation of Valbenazine for Oral Administration in Patients With Dysphagia.Clinical and translational science · 2025Trial
- Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.Journal of neurology, neurosurgery, and psychiatry · 2019Trial
- Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.Neurology · 2017Trial
- NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.Movement disorders : official journal of the Movement Disorder Society · 2015Trial
- A Case Report: Successful Management of Mixed Tardive Syndrome With Combination Pharmacotherapy in a 19-Year-Old Female With Schizophrenia.Clinical case reports · 2026Article
- Tardive blepharospasm.Journal of neurology · 2026Article
- Neuromodulation therapies in the management of tardive dyskinesia: A scoping review.Indian journal of psychiatry · 2026Review
- Tardive Dyskinesia Induced by Long-Acting Injectable Paliperidone Palmitate Once Every 3 Months in a Patient With Schizophrenia: A Case Report and Literature Review.Clinical case reports · 2026Article
- Tardive cervical dystonia.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Antipsychotic prescribing patterns and determinants in first-episode psychosis: a 2019-2024 cross-sectional study from Zambia.BMC psychiatry · 2026Article
- Plasma Metabolic Characteristics and Potential Biomarker Combinations in Schizophrenia Patients With Tardive Dyskinesia.Schizophrenia bulletin · 2026Article
- Optimal Stimulation Sites and Long-Term Efficacy of Pallidal Deep-Brain Stimulation for Patients With Tardive Dystonia.Journal of movement disorders · 2026Article
- Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings.Neurology and therapy · 2025Article
- Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review.European psychiatry : the journal of the Association of European Psychiatrists · 2025Review
- Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data.BMC psychiatry · 2025Article
- From assessment to intervention: evidence-based approaches in tardive dyskinesia.CNS spectrums · 2025Review
- Dissemination of VMAT-2 Inhibitors: A New Class Drug for Tardive Dyskinesia and Huntington Disease.Neurology. Clinical practice · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tardive dyskinesia (TD), characterized by oro-buccal-lingual stereotypy, can manifest in the form of akathisia, dystonia, tics, tremor, chorea, or as a combination of different types of abnormal movements. In addition to movement disorders (including involuntary vocalizations), patients with TD may have a variety of sensory symptoms, such as urge to move (as in akathisia), paresthesias, and pain. TD is a form of tardive syndrome-a group of iatrogenic hyperkinetic and hypokinetic movement disorders caused by dopamine receptor-blocking agents. The pathophysiology of TD remains poorly understood, and treatment of this condition is often challenging. In this update, we provide the most current information on the history, nomenclature, etiology, pathophysiology, epidemiology, phenomenology, differential diagnosis, and treatment of TD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.